These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

429 related items for PubMed ID: 25099740

  • 1. mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.
    Wang Z, Martin D, Molinolo AA, Patel V, Iglesias-Bartolome R, Degese MS, Vitale-Cross L, Chen Q, Gutkind JS.
    J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25099740
    [Abstract] [Full Text] [Related]

  • 2. The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.
    D'Amato V, Rosa R, D'Amato C, Formisano L, Marciano R, Nappi L, Raimondo L, Di Mauro C, Servetto A, Fusciello C, Veneziani BM, De Placido S, Bianco R.
    Br J Cancer; 2014 Jun 10; 110(12):2887-95. PubMed ID: 24823695
    [Abstract] [Full Text] [Related]

  • 3. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer.
    Keysar SB, Le PN, Anderson RT, Morton JJ, Bowles DW, Paylor JJ, Vogler BW, Thorburn J, Fernandez P, Glogowska MJ, Takimoto SM, Sehrt DB, Gan GN, Eagles-Soukup JR, Serracino H, Hirsch FR, Lucia MS, Thorburn A, Song JI, Wang XJ, Jimeno A.
    Cancer Res; 2013 Jun 01; 73(11):3381-92. PubMed ID: 23576557
    [Abstract] [Full Text] [Related]

  • 4. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
    Mohan S, Vander Broek R, Shah S, Eytan DF, Pierce ML, Carlson SG, Coupar JF, Zhang J, Cheng H, Chen Z, Van Waes C.
    Clin Cancer Res; 2015 Sep 01; 21(17):3946-56. PubMed ID: 25977343
    [Abstract] [Full Text] [Related]

  • 5. Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.
    Ather F, Hamidi H, Fejzo MS, Letrent S, Finn RS, Kabbinavar F, Head C, Wong SG.
    PLoS One; 2013 Sep 01; 8(2):e56112. PubMed ID: 23405260
    [Abstract] [Full Text] [Related]

  • 6. Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that PTEN Loss Contributes to Cetuximab Resistance in Head and Neck Cancer.
    Izumi H, Wang Z, Goto Y, Ando T, Wu X, Zhang X, Li H, Johnson DE, Grandis JR, Gutkind JS.
    Mol Cancer Ther; 2020 Jul 01; 19(7):1562-1571. PubMed ID: 32430488
    [Abstract] [Full Text] [Related]

  • 7. Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.
    Swick AD, Prabakaran PJ, Miller MC, Javaid AM, Fisher MM, Sampene E, Ong IM, Hu R, Iida M, Nickel KP, Bruce JY, Wheeler DL, Kimple RJ.
    Mol Cancer Ther; 2017 Jul 01; 16(7):1257-1268. PubMed ID: 28446642
    [Abstract] [Full Text] [Related]

  • 8. A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.
    Bauman JE, Arias-Pulido H, Lee SJ, Fekrazad MH, Ozawa H, Fertig E, Howard J, Bishop J, Wang H, Olson GT, Spafford MJ, Jones DV, Chung CH.
    Oral Oncol; 2013 May 01; 49(5):461-7. PubMed ID: 23384718
    [Abstract] [Full Text] [Related]

  • 9. Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9.
    E J, Xing J, Gong H, He J, Zhang W.
    Tumour Biol; 2015 Feb 01; 36(2):1091-7. PubMed ID: 25326806
    [Abstract] [Full Text] [Related]

  • 10. RAS/PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma.
    Rampias T, Giagini A, Siolos S, Matsuzaki H, Sasaki C, Scorilas A, Psyrri A.
    Clin Cancer Res; 2014 Jun 01; 20(11):2933-46. PubMed ID: 24696319
    [Abstract] [Full Text] [Related]

  • 11. Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy.
    Pogorzelski M, Ting S, Gauler TC, Breitenbuecher F, Vossebein I, Hoffarth S, Markowetz J, Lang S, Bergmann C, Brandau S, Jawad JA, Schmid KW, Schuler M, Kasper S.
    Cell Death Dis; 2014 Feb 27; 5(2):e1091. PubMed ID: 24577089
    [Abstract] [Full Text] [Related]

  • 12. Gene status of head and neck squamous cell carcinoma cell lines and cetuximab-mediated biological activities.
    Kondo N, Tsukuda M, Taguchi T, Nakazaki K, Sakakibara A, Takahashi H, Toth G, Nishimura G.
    Cancer Sci; 2011 Sep 27; 102(9):1717-23. PubMed ID: 21631644
    [Abstract] [Full Text] [Related]

  • 13. CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.
    Niehr F, Weichert W, Stenzinger A, Budach V, Tinhofer I.
    J Transl Med; 2015 Apr 01; 13():106. PubMed ID: 25890004
    [Abstract] [Full Text] [Related]

  • 14. Prevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3.
    Madera D, Vitale-Cross L, Martin D, Schneider A, Molinolo AA, Gangane N, Carey TE, McHugh JB, Komarck CM, Walline HM, William WN, Seethala RR, Ferris RL, Gutkind JS.
    Cancer Prev Res (Phila); 2015 Mar 01; 8(3):197-207. PubMed ID: 25681087
    [Abstract] [Full Text] [Related]

  • 15. A controlled trial of HNSCC patient-derived xenografts reveals broad efficacy of PI3Kα inhibition in controlling tumor growth.
    Ruicci KM, Meens J, Sun RX, Rizzo G, Pinto N, Yoo J, Fung K, MacNeil D, Mymryk JS, Barrett JW, Boutros PC, Ailles L, Nichols AC.
    Int J Cancer; 2019 Oct 15; 145(8):2100-2106. PubMed ID: 30468243
    [Abstract] [Full Text] [Related]

  • 16. Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
    Quesnelle KM, Wheeler SE, Ratay MK, Grandis JR.
    Cancer Biol Ther; 2012 Aug 15; 13(10):935-45. PubMed ID: 22785204
    [Abstract] [Full Text] [Related]

  • 17. Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors.
    Leeman-Neill RJ, Cai Q, Joyce SC, Thomas SM, Bhola NE, Neill DB, Arbiser JL, Grandis JR.
    Clin Cancer Res; 2010 May 01; 16(9):2571-9. PubMed ID: 20388852
    [Abstract] [Full Text] [Related]

  • 18. Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.
    Wirtz ED, Hoshino D, Maldonado AT, Tyson DR, Weaver AM.
    JAMA Otolaryngol Head Neck Surg; 2015 Jun 01; 141(6):543-9. PubMed ID: 25855885
    [Abstract] [Full Text] [Related]

  • 19. A retroinhibition approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancer.
    Amornphimoltham P, Patel V, Leelahavanichkul K, Abraham RT, Gutkind JS.
    Cancer Res; 2008 Feb 15; 68(4):1144-53. PubMed ID: 18281490
    [Abstract] [Full Text] [Related]

  • 20. Schedule-dependent interaction between temsirolimus and cetuximab in head and neck cancer: a preclinical study.
    Lattanzio L, Milano G, Monteverde M, Tonissi F, Vivenza D, Merlano M, Lo Nigro C.
    Anticancer Drugs; 2016 Jul 15; 27(6):533-9. PubMed ID: 26982238
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.